Literature DB >> 17964028

Diagnosis and treatment of high-grade astrocytoma.

Sith Sathornsumetee1, Jeremy N Rich, David A Reardon.   

Abstract

High-grade astrocytomas include the most common adult central nervous system (CNS) tumor, glioblastoma multiforme, and anaplastic astrocytoma--a highly aggressive cancer with short median survival despite maximal multimodality therapy. Diagnosis is by clinical and radiographic findings confirmed by histopathology. Standard-of-care therapy includes surgical resection, radiotherapy, and temozolomide. Nearly all patients who have high-grade astrocytomas develop tumor recurrence or progression after this multimodality treatment. Two treatment challenges are molecular/genetic heterogeneity of tumors and limited CNS tumor delivery. It is probable that targeted therapies will be most effective in combination with one another or with cytotoxic therapies. This article discusses diagnosis and current treatment of high-grade astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964028     DOI: 10.1016/j.ncl.2007.07.004

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  30 in total

Review 1.  Molecular profiling in glioblastoma: prelude to personalized treatment.

Authors:  Nikol Mladkova; Arnab Chakravarti
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

2.  Engineered nanoparticles for systemic siRNA delivery to malignant brain tumours.

Authors:  Johan Karlsson; Yuan Rui; Kristen L Kozielski; Amanda L Placone; Olivia Choi; Stephany Y Tzeng; Jayoung Kim; Jamal J Keyes; Max I Bogorad; Kathleen Gabrielson; Hugo Guerrero-Cazares; Alfredo Quiñones-Hinojosa; Peter C Searson; Jordan J Green
Journal:  Nanoscale       Date:  2019-10-15       Impact factor: 7.790

3.  Brain cancer stem cells display preferential sensitivity to Akt inhibition.

Authors:  Christine E Eyler; Wen-Chi Foo; Katherine M LaFiura; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Stem Cells       Date:  2008-09-18       Impact factor: 6.277

4.  lncRNAs combine and crosstalk with NSPc1 in ATRA-induced differentiation of U87 glioma cells.

Authors:  Zhikong Liang; Yuliang Wang; Hui Li; Yi Sun; Yanhua Gong
Journal:  Oncol Lett       Date:  2019-04-15       Impact factor: 2.967

5.  Family as the primary caregiver: palliative care in the Golan Heights.

Authors:  Elon Richman; Amit Ringel; Jonah Susser Kreniske; Wajdi Safadi
Journal:  BMJ Case Rep       Date:  2015-04-09

6.  Knockdown of NUPR1 inhibits the proliferation of glioblastoma cells via ERK1/2, p38 MAPK and caspase-3.

Authors:  Jun Li; Siyang Ren; Yongjian Liu; Zhigang Lian; Bin Dong; Yiqun Yao; Yinghui Xu
Journal:  J Neurooncol       Date:  2016-12-20       Impact factor: 4.130

7.  Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.

Authors:  Young-Hoon Kim; Chul-Kee Park; Won Ho Cho; In Ah Kim; Seyoung Moon; Gheeyoung Choe; Sung-Hye Park; Il Han Kim; Dong Gyu Kim; Hee-Won Jung; Min Mi Lee; So Hyun Bae; Seung Heon Cha; Chae-Yong Kim
Journal:  J Neurooncol       Date:  2010-09-24       Impact factor: 4.130

8.  Acute vomiting and mental status changes: a case of acute intraventricular haemorrhage from an optic chiasm tumour.

Authors:  Jonathan N Johnson; Ravneet K Dhillon; Jana L Anderson
Journal:  BMJ Case Rep       Date:  2009-06-01

9.  The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study.

Authors:  Jung-Won Choi; Min Mi Lee; In Ah Kim; Jee Hyun Kim; Gheeyoung Choe; Chae-Yong Kim
Journal:  J Korean Neurosurg Soc       Date:  2008-10-30

10.  IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.

Authors:  Giuseppe Minniti; Claudia Scaringi; Antonella Arcella; Gaetano Lanzetta; Domenica Di Stefano; Stefania Scarpino; Alessandro Bozzao; Andrea Pace; Veronica Villani; Maurizio Salvati; Vincenzo Esposito; Felice Giangaspero; Riccardo Maurizi Enrici
Journal:  J Neurooncol       Date:  2014-04-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.